1. Haberman Y, Karns R, Dexheimer PJ, et al. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Nat Commun. 2019;10:38.
2. Ramos GP, Papadakis KA. Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin Proc. 2019;94:155–165.
3. Armstrong H, Alipour M, Valcheva R, et al. Host immunoglobulin G selectively identifies pathobionts in pediatric inflammatory bowel diseases. Microbiome. 2019;7:1.
4. P. Langfelder and S. Horvath, “WGCNA: an R package for weighted correlation network analysis,” BMC Bioinformatics, 2008,9:599.
5. Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: mining tens of millions of expression profiles—database and tools update. Nucleic Acids Res. 2007;35(Database issue):D760–765.
6. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008.
7. Langfelder P, Zhang B, Horvath S. Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R. Bioinformatics. 2008;24:719–720.
8. Vancamelbeke M, Vanuytsel T, Farré R, et al. Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1718–1729.
9. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389:1756–1770.
10.Rubin D T, Ananthakrishnan A N, Siegel C A, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults[J]. American Journal of Gastroenterology, 2019;114:384–413.
11.MacFie TS, Poulsom R, Parker A, et al. DUOX2 and DUOXA2 form the predominant enzyme system capable of producing the reactive oxygen species H2O2 in active ulcerative colitis and are modulated by 5-aminosalicylic acid. Inflamm Bowel Dis. 2014;20:514–524.
12.Muzza M, Fugazzola L. Disorders of H2O2 generation.[J]. Best Practice & Research Clinical Endocrinology & Metabolism, 2017;31:225.
13.Sarr D, Tóth E, Gingerich A, et al. Antimicrobial actions of dual oxidases and lactoperoxidase[J]. Journal of Microbiology, 2018; 56:373.
14.Malle E, De Beer F C. Human serum amyloid A (SAA) protein: a prominent acute‐phase reactant for clinical practice[J]. European Journal of Clinical Investigation, 2015; 26:427–435.
15.O’Reilly S, Cant R, Ciechomska M, et al. Serum amyloid A induces interleukin–6 in dermal fibroblasts via Toll-like receptor 2, interleukin–1 receptor-associated kinase 4 and nuclear factor-κB[J]. Immunology, 2015; 143:331–340.
16.Ye R D, Sun L. Emerging functions of serum amyloid A in inflammation[J]. Journal of Leukocyte Biology, 2015; 98:923.
17.Gutfeld O, Prus D, Ackerman Z, et al. Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis.[J]. Journal of Histochemistry & Cytochemistry, 2006;54:63–73.
18.Schaffer M W, Smith J C, Roy T G, et al. Abstract LB–428: Upregulation of serum amyloid A1 (SAA 1) gene is associated with ulcerative colitis-related colon cancer[J]. Cancer Research, 2011, 71(8 Supplement):LB–428-LB–428.
19.Coornaert B, Carpentier I, Beyaert R. A20: Central Gatekeeper in Inflammation and Immunity[J]. Journal of Biological Chemistry, 2009;284:8217.
20. Zheng C, Huang Y, Ye Z, et al. Infantile Onset Intractable Inflammatory Bowel Disease Due to Novel Heterozygous Mutations in TNFAIP3 (A20)[J]. Inflammatory Bowel Diseases, 2018;24:2613.
21. Billmann-Born S, Till A, Arlt A, et al. Genome-Wide Expression Profiling Identifies an Impairment of Negative Feedback Signals in the Crohn\”s Disease-Associated NOD2 Variant L1007fsinsC[J]. The Journal of Immunology, 2011; 186:4027–4038.
22. Matmati M, Jacques P, Maelfait J, et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis.[J]. Nature Genetics, 2011; 43:908–912.
23. Xiao L, Qin H, Wu J, et al. Association of TNFAIP3 and TNIP1 polymorphisms with systemic lupus erythematosus risk: A meta-analysis[J]. Gene, 2018:S0378111918305523.
24. Fukaya M, Brorsson C A, Meyerovich K, et al. A20 Inhibits β-Cell Apoptosis by Multiple Mechanisms and Predicts Residual β-Cell Function in Type 1 Diabetes[J]. Molecular Endocrinology, 2016; 30:48.
25.Lee S H, Lee H R, Kwon J Y, et al. A20 ameliorates inflammatory bowel disease in mice via inhibiting NF-κB and STAT3 activation.[J]. Immunology Letters, 2018;28:198.
26. Mantovani A, Savino B, Locati M, et al. The chemokine system in cancer biology and therapy[J]. Cytokine Growth Factor Rev, 2010; 21:27–39.
27. Acharyya S, Oskarsson T, Vanharanta S, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis[J]. Cell, 2012;150:165–178.
28. Egesten A, Eliasson M, Olin AI, et al. The proinflammatory CXC-chemokines GRO-alpha/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids. Int J Colorectal Dis. 2007;22:1421–1427
29. Wang D, Sun H, Wei J, et al. CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer[J]. Cancer Research, 2017;77: 3655–3665
30. Karunakaran S, Ramachandran S, Coothankandaswamy V, et al. SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer.[J]. Journal of Biological Chemistry, 2011;286:31830–31838.
31. Rudnick G, Krämer R, Blakely R D, et al. The SLC6 Transporters: perspective on structure, functions, regulation and models for transporter dysfunction (2014)[J]. Pflügers Archiv - European Journal of Physiology, 2014; 466:25–42.
32. Sikder MOF, Yang S, Ganapathy V, Bhutia YD. The Na+/Cl—Coupled, Broad-Specific, Amino Acid Transporter SLC6A14 (ATB0,+): Emerging Roles in Multiple Diseases and Therapeutic Potential for Treatment and Diagnosis. AAPS J. 2017;20:12
33. Babu E, Bhutia Y D, Ramachandran S, et al. Deletion of the amino acid transporter Slc6a14 suppresses tumor growth in spontaneous mouse models of breast cancer.[J]. Biochemical Journal, 2015;469:17–23.
34. Coothankandaswamy V, Cao S, Xu Y, et al. Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer[J]. Br J Pharmacol, 2016;173:3292–3306.
35. Sewda K, Enkemann S, Gillies R J, et al. Abstract 3178: Identification and validation of markers for colon adenoma and adenocarcinoma[J]. Cancer Research, 2011; 71(8 Supplement):3178–3178.
36. Flach C F, Eriksson A, Jennische E, et al. Detection of elafin as a candidate marker for ulcerative colitis by whole-genome microarray screening[J]. Inflammatory Bowel Diseases, 2006;12:837–842.
37. Novak E A, Mollen K P. Mitochondrial dysfunction in inflammatory bowel disease[J]. Frontiers in Cell & Developmental Biology, 2015;3:62.
38. Kolios G, Valatas V, Ward S G. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle[J]. Insect Science, 2010;113:427–437.
39. van der Post S, Jabbar KS, Birchenough G, et al. Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis. Gut. 2019;0,1–10
40. Hamann J, Vogel B, van Schijndel G M, et al. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF)[J]. Journal of Experimental Medicine, 1996;184:1185–1189.
41. He Z, Wu H, Jiao Y, et al. Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer.[J]. Oncology Letters, 2015;9:793–797.
42. Saygin C, Wiechert A, Rao V S, et al. CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors[J]. Journal of Experimental Medicine, 2017;214:2715.
43. Cimmino F, Avitabile M, Pezone L, et al. CD55 is a HIF–2α marker with anti-adhesive and pro-invading properties in neuroblastoma:[J]. Oncogenesis, 2016;5:e212.
44. Inaba T, Mizuno M, Ohya S, et al. Decay-accelerating factor (DAF) in stool specimens as a marker of disease activity in patients with ulcerative colitis (UC).[J]. Clinical & Experimental Immunology, 2010;112:237–241.
45. Andoh A, Fujiyama Y, Kimura T, et al. Increased expression of decay-accelerating factor (CD55) in the inflamed mucosa of patients with ulcerative colitis[J]. Pathophysiology, 1998;5:105–110.
46. Axelrad JE, Joelson A, Green PHR, et al. Enteric Infections Are Common in Patients with Flares of Inflammatory Bowel Disease. Am J Gastroenterol. 2018;113:1530–1539.
47. Forbes JD, Chen CY, Knox NC, et al. A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?. Microbiome. 2018;6:221